Autus Asset Management LLC Reduces Position in Edwards Lifesciences Corp (EW)

Autus Asset Management LLC Reduces Position in Edwards Lifesciences Corp (EW)

Autus Asset Management LLC decreased its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 3.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,031 shares of the medical research company’s stock after selling 1,402 shares during the period. Edwards Lifesciences makes up 1.3% of Autus Asset Management LLC’s investment portfolio, making the stock its 29th largest holding. Autus Asset Management LLC’s holdings in Edwards Lifesciences were worth $8,042,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Insight Partners LLC boosted its stake in Edwards Lifesciences by 0.5% during the first quarter. Capital Insight Partners LLC now owns 11,010 shares of the medical research company’s stock worth $2,107,000 after acquiring an additional 53 shares in the last quarter. Cetera Advisor Networks LLC lifted its stake in shares of Edwards Lifesciences by 3.8% in the fourth quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock worth $242,000 after buying an additional 57 shares in the last quarter. Kentucky Retirement Systems lifted its stake in shares of Edwards Lifesciences by 0.7% in the fourth quarter. Kentucky Retirement Systems now owns 9,093 shares of the medical research company’s stock worth $1,393,000 after buying an additional 60 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of Edwards Lifesciences by 11.2% in the fourth quarter. Parallel Advisors LLC now owns 684 shares of the medical research company’s stock worth $101,000 after buying an additional 69 shares in the last quarter. Finally, BB&T Securities LLC lifted its stake in shares of Edwards Lifesciences by 0.9% in the fourth quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock worth $1,252,000 after buying an additional 70 shares in the last quarter. 84.62% of the stock is currently owned by hedge funds and other institutional investors.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $176.90, for a total transaction of $5,802,320.00. Following the completion of the sale, the chief executive officer now directly owns 75,926 shares of the company’s stock, valued at $13,431,309.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Larry L. Wood sold 6,716 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $192.34, for a total transaction of $1,291,755.44. Following the sale, the vice president now directly owns 122,495 shares of the company’s stock, valued at $23,560,688.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 152,437 shares of company stock valued at $26,836,405. 1.63% of the stock is owned by corporate insiders.

Several brokerages have recently issued reports on EW. Deutsche Bank upped their target price on shares of Edwards Lifesciences from $164.00 to $184.00 and gave the stock a “hold” rating in a research note on Wednesday, April 24th. Jefferies Financial Group upped their target price on shares of Edwards Lifesciences from $195.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. BMO Capital Markets upped their target price on shares of Edwards Lifesciences to $204.00 and gave the stock an “outperform” rating in a research note on Friday, March 22nd. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $203.00 target price on the stock in a research note on Thursday, April 25th. Finally, BTIG Research reiterated a “hold” rating on shares of Edwards Lifesciences in a research note on Wednesday, April 24th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $187.19.

EW opened at $177.77 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.66 and a quick ratio of 2.69. Edwards Lifesciences Corp has a twelve month low of $133.34 and a twelve month high of $197.86. The company has a market cap of $37.22 billion, a PE ratio of 37.82, a P/E/G ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The firm had revenue of $993.00 million during the quarter, compared to analysts’ expectations of $989.87 million. During the same period in the previous year, the company earned $1.22 earnings per share. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. As a group, research analysts predict that Edwards Lifesciences Corp will post 5.28 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: How Investors Use a Balance Sheet

Related posts

Leave a Comment